Physician profile
Allison Rayner
NPI 1275907446
$5,642.31
in general payments reported to CMS, 2019-2025
28 companies · $1,446 in 2025
The $1,446 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,277 · 2022: $929 · 2023: $833 · 2024: $1,157 · 2025: $1,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,436.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,474.76 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $645.41 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $391.34 | 2022-2025 | Sotyktu |
| Revance Therapeutics, INC. | $343.71 | 2024-2025 | Daxi, Daxxify |
| Pfizer INC. | $281.62 | 2021-2025 | |
| Incyte Corporation | $273.67 | 2022-2025 | Opzelura |
| Biofrontera INC. | $220.52 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Galderma Laboratories, L.P. | $199.52 | 2021-2025 | Nemluvio |
| Almirall LLC | $182.40 | 2021-2025 | Klisyri, Seysara |
| Arcutis Biotherapeutics, INC. | $181.40 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $146.03 | 2021-2025 | |
| Leo Pharma INC. | $132.37 | 2021-2024 | Adbry |
| Vyne Pharmaceuticals INC. | $119.23 | 2021 | |
| Organogenesis INC. | $109.26 | 2022-2025 | Puraply, Novachor |
| Amgen INC. | $107.89 | 2021-2025 | Otezla, Otezla |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $106.41 | 2021-2025 | Ebglyss, Taltz |
| Regeneron Healthcare Solutions, INC. | $100.80 | 2023-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $92.51 | 2021-2022 | |
| Ucb, INC. | $91.07 | 2024-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $83.00 | 2021-2024 | Jublia, Cabtreo, Arazlo |
| Lnhc, INC | $74.61 | 2025 | Zelsuvmi |
| Genzyme Corporation | $72.95 | 2021-2022 | |
| Allergan, INC. | $67.20 | 2022 | |
| Merz North America, INC. | $37.31 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $34.71 | 2023-2024 | Ycanth |
| Botanix Sb INC | $31.23 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $22.94 | 2023-2025 | |
| Paratek Pharmaceuticals, INC. | $18.44 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Rayner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.